30:00 EST to highlight the unmet medical need of cancer therapy-related diarrhea and Jaguar’s Mental Health Entheogen Therapeutic Initiative (ETI) to discover new therapies derived from psychoactive plants

The webcast will include:

Commentary by Leading Medical Oncologist and Breast Cancer Hematologist Lee Schwartzberg, MD, FACP on the Unmet Need for a Targeted, Biologics Approach to the Management of Cancer Therapy-Related Diarrhea

A presentation by ethnobotanist, anthropologist, bestselling author and former National Geographic Explorer-in-Residence Dr. Wade Davis on the history and traditional uses of psychoactive plants and their potential to treat unmet mental health needs

Click here to register for the webcast

SAN FRANCISCO, CA / ACCESSWIRE / January 11, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) issued a reminder today that the company will conduct a webcast for investors tomorrow, Thursday, January 12, 2023, at 10:30 am Eastern Standard Time to highlight the high unmet need associated with cancer therapy – related diarrhea (CTD). The webcast will include highlights of the recently recorded commentary by Lee Schwartzberg, MD, FACP, a renowned breast cancer oncologist, on the unmet need for a targeted, biologic approach to managing cancer therapy-related diarrhea.

Dr. Schwartzberg, a leading breast cancer oncologist and hematologist, serves as chief of medical oncology and hematology at Renown Health-William N. Pennington Cancer Institute in Reno, Nevada and previously served as director executive of the West Clinic in Memphis, Tennessee.

The webcast will also provide updates on the mental health company’s Entheogen Therapeutics Initiative (ETI) to uncover new therapeutic opportunities derived from psychoactive plants. Ethnobotanist, anthropologist, bestselling author and former National Geographic Explorer-in-Residence Wade Davis, PhDProfessor of Anthropology and Leadership Chair in Cultures and Ecosystems at Risk at the University of British Columbia, he will join the webcast to talk about the history and traditional uses of psychoactive plants and their potential to treat unmet mental health needs.

Instructions for attending the webcast

When: Thursday, January 12, 2023 at 10:30 am Eastern Standard Time

Participant registration and access link: Click here

Learn about diarrhea related to cancer therapy

A significant proportion of patients receiving cancer therapy experience diarrhea, and diarrhea has the potential to lead to dehydration, potential infections, and treatment nonadherence in this population. New “targeted cancer therapy” agents, such as epidermal growth factor receptor (EGFR) antibodies and tyrosine kinase inhibitors (TKIs), with or without cycle chemotherapy agents, may cause an increase in the content of electrolytes and fluids in the intestinal lumen, resulting in the passage of loose/watery stools (i.e. diarrhea). Diarrhea has been reported as one of the most common side effects of TKIs and may result in interruptions of anticancer therapy or reductions in therapeutic dose, potentially impacting patient outcome. Diarrhea is also a common side effect of some approved CDK 4/6 inhibitors.

Information about Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics and Jaguar Animal Health

Jaguar Health, Inc. is a commercial-stage pharmaceutical company focused on the development of new, plant-based, non-opioid and sustainably derived prescription medicines for people and animals with gastrointestinal disorders, including chronic and debilitating diarrhea. Jaguar Health’s wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on the development and commercialization of proprietary plant-based human pharmaceutical products from plants responsibly harvested in rainforest areas. Our crophelemer drug candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for diarrhea prophylaxis in adult cancer patients receiving targeted therapy. Jaguar Health is the majority shareholder of Napo Therapeutics SpA (f/k/a Napo EU SpA), an Italian company founded by Jaguar Health in Milan, Italy in 2021, which focuses on expanding access to crophelemer in Europe . Jaguar Animal Health is a trading name of Jaguar Health.

For more information about Jaguar Health, visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements”. These include statements regarding the expectation that Jaguar Health will hold a webcast for investors on 12 January 2023. In some instances, forward-looking statements can be identified with terms such as “may”, “will”, “should”, “expect,” ” plan”, “aim”, “anticipate”, “can”, “intend”, “aim”, “project”, “contemplate”, “believe”, “estimate”, “foresee”, “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are predictions only. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be anticipated or quantified and others are beyond the control of Jaguar. Except as required by applicable law, Jaguar does not intend to publicly update or revise any forward-looking statements contained herein, whether as a result of new information, future events, changed circumstances or otherwise.

Contact:

Peter Hodge
Jaguar Health, Inc.
[email protected]
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the source version at accesswire.com:
https://www.accesswire.com/734690/REMINDER-Jaguar-Health-to-Hold-Investor-Webcast-Thursday-January-12th-at-1030-AM-EST-to-Highlight-Unmet-Medical-Need- of-Cancer-Therapy-related-Diarrhea-and-Jaguars-Mental-Health-Entheogen-Therapeutics-Initiative-ETI-to-discover-new-therapies

Add a Comment

Your email address will not be published. Required fields are marked *